Abstract
In This Issue...
Target-based drug discovery has become the prevailing paradigm used by
pharmaceutical and biotechnology companies. This approach is appealing because
it holds the promise of identifying more-efficacious compounds with fewer
undesirable side effects. Companies have therefore invested significant
resources in acquiring and developing technologies for identifying and
validating new drug targets. This report explores both state-of-the-art and
emerging target identification and validation technologies and methods. We
consider the limitations of these technologies and their impact on drug
discovery, examine relevant business models, and profile selected companies
with novel target identification and validation technologies.
| 
View Cart
